The Clinical Effect of Deferoxamine Mesylate on Edema after Intracerebral Hemorrhage

BACKGROUND AND PURPOSE It has been shown that 3 days of 62 mg/kg/day deferoxamine infusion (maximum dose not to exceed 6000 mg/day) is safe and tolerated by intracerebral hemorrhage (ICH) patients. The aim of this study was to investigate the efficacy of deferoxamine mesylate for edema resolution and hematoma absorption after ICH. METHODS From February 2013 to May 2014, spontaneous ICH patients diagnosed by computed tomography (CT) within 18 hours of onset were evaluated. Patients were randomly divided into two groups: an experimental group and a control group. The treatment of the two groups was similar except that the experimental group received deferoxamine mesylate. Patients were evaluated by CT and neurology scale at the time of admission, and on the fourth, eighth, and fifteenth day (or at discharge) after admission. Patients were followed up for the first 30 days and clinical data of the two groups were compared. RESULTS Forty-two patients completed 30 days of follow-up by May 2014; 21 cases in the experimental group and 21 cases in the control group. The control group's relative edema volume on the fifteenth day (or discharge) was 10.26 ± 17.54, which was higher than the experimental group (1.91 ± 1.94; P < 0.05). The control group's 1-8 day and 8-15 day relative hematoma absorption were greater than the experimental group (P < 0.05).The control group's relative edema volume on the fourth, eighth, and fifteenth day (or discharge) was higher than the experimental group (P < 0.05). Neurological scores between the two groups were not statistically different on the fifteenth day (or discharge) or on the thirtieth day. CONCLUSIONS Deferoxamine mesylate may slow hematoma absorption and inhibit edema after ICH, although further investigation is required to form definitive conclusions. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR-TRC-14004979.

[1]  J. Corvol,et al.  Targeting chelatable iron as a therapeutic modality in Parkinson's disease. , 2014, Antioxidants & redox signaling.

[2]  Lori Shutter,et al.  A trial of intracranial pressure monitoring in traumatic brain injury , 2014, Critical Care.

[3]  A. Munnich,et al.  Regional siderosis: a new challenge for iron chelation therapy , 2013, Front. Pharmacol..

[4]  T. Hatakeyama,et al.  Deferoxamine Reduces Neuronal Death and Hematoma Lysis After Intracerebral Hemorrhage in Aged Rats , 2013, Translational Stroke Research.

[5]  H. Yi,et al.  Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage , 2012, Neurological Sciences.

[6]  G. Schlaug,et al.  Safety and Tolerability of Deferoxamine Mesylate in Patients With Acute Intracerebral Hemorrhage , 2011, Stroke.

[7]  S. Kasner,et al.  Anti-Adrenergic Medications and Edema Development after Intracerebral Hemorrhage , 2011, Neurocritical care.

[8]  M. Mlynash,et al.  Natural History of Perihematomal Edema After Intracerebral Hemorrhage Measured by Serial Magnetic Resonance Imaging , 2011, Stroke.

[9]  Ivan S. Kotchetkov,et al.  Advances in Neuroprotective Strategies: Potential Therapies for Intracerebral Hemorrhage , 2010, Cerebrovascular Diseases.

[10]  T. Schallert,et al.  Deferoxamine Treatment for Intracerebral Hemorrhage in Aged Rats: Therapeutic Time Window and Optimal Duration , 2010, Stroke.

[11]  C. Anderson,et al.  Significance of perihematomal edema in acute intracerebral hemorrhage , 2009, Neurology.

[12]  R. Keep,et al.  Deferoxamine Reduces Intracerebral Hematoma-Induced Iron Accumulation and Neuronal Death in Piglets , 2009, Stroke.

[13]  R. Keep,et al.  Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. , 2009, Stroke.

[14]  V. Feigin,et al.  Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review , 2009, The Lancet Neurology.

[15]  S. Yoshida,et al.  Serum S100B, brain edema, and hematoma formation in a rat model of collagenase-induced hemorrhagic stroke , 2009, Brain Research Bulletin.

[16]  W. Qing,et al.  Brain edema after intracerebral hemorrhage in rats: the role of iron overload and aquaporin 4. , 2009, Journal of neurosurgery.

[17]  M. Selim.  Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials. , 2009, Stroke.

[18]  M. Selim,et al.  The Relationship between Hematoma Iron Content and Perihematoma Edema: An MRI Study , 2009, Cerebrovascular Diseases.

[19]  William D Freeman,et al.  Computer-Assisted Volumetric Analysis Compared With ABC/2 Method for Assessing Warfarin-Related Intracranial Hemorrhage Volumes , 2008, Neurocritical care.

[20]  J. Dawson,et al.  Acute stroke: we have the treatments and we have the evidence – we need to use them , 2007, Critical care.

[21]  R. Keep,et al.  Mechanisms of brain injury after intracerebral haemorrhage , 2006, The Lancet Neurology.

[22]  P. Langhorne,et al.  Poor outcome in primary intracerebral haemorrhage: results of a matched comparison , 2004, Postgraduate Medical Journal.

[23]  R. Regan,et al.  Hemin induces an iron‐dependent, oxidative injury to human neuron‐like cells , 2003, Journal of neuroscience research.

[24]  V. Feigin,et al.  Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century , 2003, The Lancet Neurology.

[25]  Joseph P Broderick,et al.  Natural History of Perihematomal Edema in Patients With Hyperacute Spontaneous Intracerebral Hemorrhage , 2002, Stroke.

[26]  A. Fergus,et al.  Systemic administration of the iron chelator deferiprone attenuates subarachnoid hemorrhage-induced cerebral vasospasm in the rabbit. , 1997, Neurosurgery.

[27]  R. Koehler,et al.  Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs. , 1995, Stroke.

[28]  C. Palmer,et al.  Deferoxamine Posttreatment Reduces Ischemic Brain Injury in Neonatal Rats , 1994, Stroke.

[29]  L. R. Caplan,et al.  Intracerebral haemorrhage , 1992, The Lancet.

[30]  H. Keberle.  The Biochemistry of Desferrioxamine and its Relation to Iron Metabolism , 1964, Annals of the New York Academy of Sciences.

[31]  L. Defebvre,et al.  Targeting Chelatable Iron as a Therapeutic Modality in Parkinson ’ s Disease , 2016 .

[32]  C. Anderson.  Perihematomal edema as predictor of outcome , 2014, Journal of neurosciences in rural practice.

[33]  R. Keep,et al.  Iron accumulation and DNA damage in a pig model of intracerebral hemorrhage. , 2011, Acta neurochirurgica. Supplement.